COGT | Cogent Biosciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	7.66 - 7.87
52 Week Range	4.28 - 12.61
Beta	0.03
Implied Volatility	96.73%
IV Rank	37.81%
Day's Volume	295,836
Average Volume	1,403,191
Shares Outstanding	110,462,000
Market Cap	858,289,740
Sector	Healthcare
Industry	Biotechnology
IPO Date	2018-03-29

Valuation
Profitability
Growth
Health
P/E Ratio	-3.13
Forward P/E Ratio	N/A
EPS	-2.48
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	164
Country	USA
Website	COGT

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

COGT's peers: AGIO, CLDX, LRMR, KURA, KNSA, CERE, IDYA, ANAB, MGTX, KROS, FIXX, SANA, OLMA, CGEM, LIFE, ZNTL, SNDX, KALV, MRSN, VTYX, PTGX, VRNA, TVTX, VERA

*Chart delayed

Analyzing fundamentals for COGT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see COGT Fundamentals page.

Watching at COGT technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on COGT Technicals page.